ECONOMY AND DIGITAL TRANSFORMATION IMPACTING HEALTHCARE COMPANIES

Carmen Naicu and Razvan Serbu ()
Additional contact information
Carmen Naicu: Novartis

Revista Economica, 2020, vol. 72, issue 3, 66-74

Abstract: Traditional model of developing drugs was slow and very expensive, relying on the face to face interactions only. In the meantime, increasing numbers of new molecules that are studied in clinical trials to become drugs required more and more investment, which derived to a reduced reimbursement. What if the patients can benefit more on the digital medicine and treating chronic diseases on digital medicine but also some of the acute symptoms? The aim of research, was to evaluate the impact on the companies reimbursement of "GO Digital" alternatives as well as the impact of patient's life quality

Keywords: digitalization; e-health; m-heath (search for similar items in EconPapers)
JEL-codes: I15 O33 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://economice.ulbsibiu.ro/revista.economica/archive/72306naicu&serbu.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:blg:reveco:v:72:y:2020:i:3:p:66-74

Access Statistics for this article

More articles in Revista Economica from Lucian Blaga University of Sibiu, Faculty of Economic Sciences Lucian Blaga University of Sibiu, Faculty of Economic Sciences Dumbravii Avenue, No.17, postal code 550324, Sibiu, Romania. Contact information at EDIRC.
Bibliographic data for series maintained by Eduard Alexandru Stoica ().